Introduction

Cataract is the clouding of the clear lens of the eye, where patients often find difficulties in sight, through the cloudy lenses, like looking through a frosty or fogged-up window. Some of the major cataract types include nuclear cataract, cortical cataract, posterior subcapsular cataract, and congenital cataract. The clumps of protein reduce the sharpness of the image reaching the retina. With time, the cloudy area in the lens becomes larger, seeing becomes more difficult, and vision becomes blurrier.

In most of the adult population, the disease becomes more prominent after the age of 40. Most of the time, the patient opts for cataract surgery. Companies are identifying new high-tech intraocular lens (IOL). With that in the development of therapeutics, the focus is on the development of molecules, to delay or prevent the formation of cataracts, with heat shock proteins, also known as alpha crystalline, which prevents misfolded proteins from aggregating in the lens of the eye.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors that have pipeline products for the concerned market.

Cataract Clinical Trial Analysis by Phase and Status

• The clinical trial analysis for cataract indicates that there are around XX number of trials under various phases
• Phase X trials accounted for the majority share
• The trial data analysis suggests a number of ongoing trials, as well as ones that have been terminated

Cataract Clinical Trials Analysis, by Geography

• By geography, the scope of the report covers the regional assessment for the clinical trials, globally. It covers a concise information of registered clinical trials in different countries across several developed and emerging markets
• This disease is highly prevalent across the older population, globally. Although there are effective treatments available through surgical procedures, many adults have to cope with an extended period of vision impairment, before surgical removal, if the retina is completely diseased. Technological advancements and high investments in the research of drug therapies and devices majorly drive this market

Key Sponsors in Cataract Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you to understand

• The number of clinical trials that are being conducted worldwide
• The key products under development (Phase I, Phase II, and Phase III)
• The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
• The average recruitment size in trials
• Key deals between institutions and industries
• Insights on regional- and country-level data
• Dormant and discontinued studies across the category
• Information on key sponsors and profiles
• Protocol and design comparisons, to generate the best solution for your product development strategy